Zobrazeno 1 - 10
of 392
pro vyhledávání: '"35"'
Autor:
Zi Chen, Mohammad Ahmad, Matthew S. Davids, Asher Chanan-Khan, H. Miles Prince, Mingyu Li, Constantine S. Tam, Marina Konopleva, Zhicong He, Boyd Mudenda, Yifan Zhai, Sikander Ailawadhi, Ming Lu, Bo Huang, Masa Lasica, Costas K. Yannakou, David A. Rizzieri, Zhiyan Liang, Dajun Yang, Danielle M. Brander
Publikováno v:
Journal of Clinical Oncology. 39:7502-7502
7502 Background: The BCL-2i venetoclax is active in certain HMs but can increase the risk of tumor lysis syndrome (TLS), requiring a 5-week dose ramp-up for CLL patients. Cases of severe neutropenia with venetoclax treatment have also been reported.
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Atsushi Sato, Yasushi Tsuji, Takahide Sasaki, Shintaro Nakano, Susumu Sogabe, Atsushi Ishiguro, Hiroshi Nakatsumi, Satoshi Yuki, Yoshito Komatsu, Masayoshi Dazai, Osamu Muto, Yuh Sakata, Hiroyuki Okuda, Kentaro Sawada, Kazuaki Harada, Naoya Sakamoto, Mari Sekiguchi, Yasuyuki Kawamoto, Michio Nakamura, Yoshiaki Shindo
Publikováno v:
Journal of Clinical Oncology. 39:217-217
217 Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared with PTX alone for advanc
Autor:
Ramona F. Swaby, Barbara Burtness, Lisa Licitra, Makoto Tahara, Jean-Pascal Machiels, Ezra E.W. Cohen, Danny Rischin, Lillian L. Siu, Cecilia Pinheiro, Kevin J. Harrington, Ying Zhu, Chooi Peng Lee
Publikováno v:
Journal of Clinical Oncology. 38:TPS6589-TPS6589
TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of pembrolizumab plus
Autor:
Kate Fitch, Scott C. Flanders, Michael T. Schweizer, Rana R. McKay, Christine Ferro, Michael D. Fabrizio
Publikováno v:
Journal of Clinical Oncology. 38:42-42
42 Background: Since the mCRPC treatment landscape is evolving, we examined real-world use and outcomes of sipuleucel-T (sip-T) and oral agents (abiraterone acetate and enzalutamide) in men with mCRPC. Methods: Using Medicare FFS Identifiable Researc
Autor:
Nina Tunariu, Roberto Alonzi, Holly Tovey, John Staffurth, Helen Stidwill, Matthew D. Blackledge, Alison Tree, Chris Parker, Sophie Perry, Emma Hall, Dow-Mu Koh, Anwar R. Padhani, Peter Chatfield, Jessica Finch
Publikováno v:
Journal of Clinical Oncology. 37:e16513-e16513
e16513 Background: Ra-223 improves overall survival in patients with mCRPC, but is associated with increased risk of fracture when used in combination with abiraterone and prednisolone. We have assessed time to first new fracture in men with mCRPC re
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit
Autor:
Kazushiro Kawaguchi, Katsuyoshi Hashine, Hidehisa Noguchi, Karim Fizazi, Mary B. Todd, Hiro-omi Kanayama, Hisashi Hasumi, Tomohiro Tsuchiya, Namphuong Tran, Fuminori Sato, Hiroaki Matsumoto, Hirotsugu Uemura, Kentaro Enjo, Hiroyoshi Suzuki, Mototsugu Oya, Nobuaki Matsubara, Satoshi Fukasawa
Publikováno v:
Journal of Clinical Oncology. 36:286-286
286 Background: Patients with high-risk mHNPC have a poor prognosis. In Japan, mHNPC accounts for approximately 10% of newly diagnosed prostate cancers. AAP was approved for the treatment of castration-resistant prostate cancer in Japan in July 2014.
Autor:
Antoine Hollebecque, Andrés Cervantes, Aitana Calvo, Thierry André, Aude Valette, Ronan Fougeray, Catherine Leger, Nadia Amellal, Josep Tabernero, Guillem Argiles
Publikováno v:
Journal of Clinical Oncology. 36:816-816
816 Background: Preclinical evidence suggests improved efficacy when combining trifluridine/tipiracil with oxaliplatin compared to each monotherapy (Nukatsuka, 2015). The primary objective was to determine the MTD and the safety profile of the double
Publikováno v:
Journal of Clinical Oncology. 24:1454-1458
Purpose A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if t